Abstract:AIM:To evaluate the relationship between intravitreal bevacizumab (IVB) treatment and the levels of vitreous vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and vitreous-retina surface fibrosis in patients with proliferative diabetic retinopathy (PDR).METHODS:This study was a prospective, open-label, controlled, randomized clinical trial. Sixty-eight eyes of PDR patients (n=53) and macular hole patients (n=15) were enrolled in this study. Thirty-four eyes of the PDR patients received IVB before vitrectomy. Twenty-three of the 34 PDR patients received IVB treatment 5d before vitrectomy (subgroup a), and 11 of the 34 PDR patients received IVB treatment greater than 2wk prior to vitrectomy (subgroup b). Nineteen of the PDR patients did not receive IVB treatment at any time prior to vitrectomy. The levels of bFGF and VEGF in vitreous samples were measured using enzyme-linked immunosorbent assay (ELISA) and the degree of vitreoretinal fibrosis was characterized using clinical data and data obtained intra-operatively.RESULTS:In PDR patients, VEGF and bFGF levels were significantly increased compared to non-PDR (control) subject's eyes (P<0.01). In PDR patients, vitreous VEGF levels were significantly decreased following IVB treatment compared to PDR patients that did not receive IVB treatment (P<0.01). The degree of vitreoretinal fibrosis was significantly increased in subgroup b compared to subgroup a(P<0.05) and to patients that did not receive IVB (P<0.05). Vitreous bFGF levels were significantly greater in subgroup b than subgroup a (P<0.01) or in patients who did not receive IVB treatment (P<0.05). A Spearman's rank correlation test indicated that higher levels of vitreous bFGF, but not VEGF, correlated with the degree of vitreoretinal fibrosis.CONCLUSION:We found that bFGF levels increase in PDR patient's vitreous after IVB treatment longer than two weeks prior to vitrectomy and correlated with the degree of fibrosis after IVB treatment. These findings suggest vitreous fibrosis is increased in PDR patients after IVB treatment may be due to increased levels of bFGF.

Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab.

Changes in Vitreous VEGF, Bfgf and Fibrosis in Proliferative Diabetic Retinopathy after Intravitreal Bevacizumab.

Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema.

Preoperative Timing of Intravitreal Bevacizumab Injection for Proliferative Diabetic Retinopathy Patients

Change of Vascular Endothelial Growth Factor Levels Following Vitrectomy in Eyes with Proliferative Diabetic Retinopathy

Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy.

Effects of Bevacizumab on CTGF and PEDF in Proliferative Membrane in Patients with PDR

Effect of an intravitreal injection of bevacizumab on the expression of VEGF and CD34 in the retina of diabetic rats: Bevacizumab a retinal anti-angiogenesis

Decreased Prothrombin Time after Intravitreal Bevacizumab in the Early Period in Patients with Proliferative Diabetic Retinopathy

Vitreous Fibronectin and Fibrinogen Expression Increased in Eyes with Proliferative Diabetic Retinopathy after Intravitreal Anti-VEGF Therapy

The Relationship Between Anti-Vascular Endothelial Growth Factor and Fibrosis in Proliferative Retinopathy: Clinical and Laboratory Evidence

Reduced Expression of Erythropoietin After Intravitreal Ranibizumab in Proliferative Diabetic Retinopathy Patients—Retrospective Interventional Study

Anti-Vascular Endothelial Growth Factor Therapy as an Adjunct to Diabetic Vitrectomy

Six-month Changes in Cytokine Levels after Intravitreal Bevacizumab Injection for Diabetic Macular Oedema and Macular Oedema Due to Central Retinal Vein Occlusion

Study on Vascular Endothelial Growth Factor and Pigment Epithelium-derived Factor in Vitreous of Diabetic Retinopathy

Clinical observation of intravitreal injection with Bevacizumab for iris neovascularization

Effects of Apelin and Vascular Endothelial Growth Factor on Central Retinal Vein Occlusion in Monkey Eyes Intravitreally Injected with Bevacizumab: a Preliminary Study.

Evaluation of Foveal Vasculature by Optical Coherence Tomography Angiography after Pan-Retinal Photocoagulation versus Intravitreal Anti-VEGF Injections

Vascular endothelial growth factor/connective tissue growth factor and proteomic analysis of aqueous humor after intravitreal conbercept for proliferative diabetes retinopathy

Prophylactic intravitreal injection of aflibercept for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy: A randomized controlled trial

Inhibition of Neovascularization and Expression Shift of Pro-/Anti-Angiogenic Vascular Endothelial Growth Factor Isoforms after Intravitreal Bevacizumab Injection in Oxygen-Induced-Retinopathy Mouse Model